Nipro Vialex – 26th January 2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Nasal & Pulmonary Drug Development
Novo Nordisk 20 March 2024, 11:21
Carterra – 24th March 2025

AstraZeneca’s Soliris approved in Japan for paediatric gMG patients

The drug is the first to be approved in Japan to treat children and adolescents with generalised myasthenia gravis.

AstraZeneca has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Soliris (eculizumab) for the extended use of treating generalised myasthenia gravis (gMG) in paediatric patients who are anti-acetylocholine receptor (AChR) antibody-positive and whose symptoms are difficult to control with other treatments.

This drug is the first to be approved in Japan for the treatment of children and adolescents with gMG, with approval following results from a phase 3 trial of Soliris. This trial demonstrated clinical benefit in indicating this in patients who previously failed immunosuppressive treatment.

Keiko Ishigaki, Department of Pediatrics at Tokyo Women’s Medical University, School of Medicine, Japan, commented: “gMG is challenging to manage in paediatric patients, as current therapies available to this population, such as immunosuppressants, may not offer adequate control as the disease progresses.

“[The] expanded approval of Soliris in Japan demonstrates the impact of C5 complement inhibition in treating gMG, offering paediatric patients a targeted option with the potential to preserve muscle function and reduce disease severity.”

Marc Dunoyer, chief executive officer of Alexion, a subsidiary of AstraZeneca, added: “Paediatric patients living with gMG can become nonresponsive to standard treatments and continue to experience symptoms that impact their mobility, speech and breathing.

“Our first-in-class C5 inhibitor Soliris has the potential to improve outcomes and quality of life for paediatric patients and their families, and we take pride in delivering this first and only targeted therapy to the paediatric gMG community in Japan.”

Scott Pharma – 25.03.2025
SMI – 24/03/2025
Chemspec Europe – 27.02.2025
PHARMAP: Mon 14 October 2024, 10.36
FujiFilm Skyscraper: 26th November 2024
Woolcool 26 March 2024, 16:16
Biopharma group 6 March 2024, 09:40
EyeC 18 March 2024, 13:10
L.B. Bohle – 08.04.2025